deCODE genetics (Nasdaq:DCGN) today
announced that its presentation at Nasdaq's U.S. Small Cap Conference
will be webcast live. deCODE CEO Dr. Kari Stefansson will provide an
overview of the company's drug development programs and business.
The presentation will be delivered at 10am GMT/5am EST on Wednesday,
February 8, 2006, at the Merrill Lynch Financial Centre in London. The
webcast can be accessed through the Investors page on deCODE's website,
www.decode.com, or through the Nasdaq website at http://investors.nasdaq.com.
The webcast will be archived for at least one week on both sites. Those
interested in listening should log on a few minutes in advance, in
order to download any software or complete any sign-in that may be
required.
About deCODE
deCODE genetics (Nasdaq:DCGN) is a
biopharmaceutical company applying its discoveries in human genetics to
the development of drugs for common diseases. deCODE is a global leader
in gene discovery - our population approach and resources have
enabled us to isolate key genes contributing to major public health
challenges from cardiovascular disease to cancer, genes that are
providing us with drug targets rooted in the basic biology of disease.
deCODE is also leveraging its expertise in human genetics and
integrated drug discovery and development capabilities to offer
innovative products and services in DNA-based diagnostics,
bioinformatics, genotyping, structural biology, drug discovery and
clinical development. deCODE is delivering on the promise of the new
genetics.SM Visit us on the web at www.decode.com.
